Evidence map›Paper›PMID 30418989›Full record

ArticlePloS one2018

Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR).

Rania Abu Seir, Kifaya Azmi, Ayob Hamdan, Hanan Namouz, Fuad Jaar, Hanaa Jaber, Carmit Rubin, Dafna Doron, Galia Rahav, Ziad Abdeen and 1 more

Abstract readComparative Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Serotype Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in Older Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rania Abu SeirAl-Quds University, Abu-Dis, Palestine.ORCID 0000-0002-4625-9742
Kifaya AzmiAl-Quds University, Abu-Dis, Palestine.
Ayob HamdanIndependent Researcher, Nabulus, Palestine.
Hanan NamouzMacabbi Healthcare Services, Jerusalem, Israel.
Fuad JaarIndependent Researcher, Bethlehem, Palestine.
Hanaa JaberSheba Medical Center, Ramat-Gan, Israel.
Carmit RubinSheba Medical Center, Ramat-Gan, Israel.
Dafna DoronMacabbi Healthcare Services, Jerusalem, Israel.
Galia RahavSheba Medical Center, Ramat-Gan, Israel.
Ziad AbdeenAl-Quds University, Abu-Dis, Palestine.
Gili Regev-YochaySheba Medical Center, Ramat-Gan, Israel.ORCID 0000-0001-7163-4607

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPneumococcal conjugate vaccines (PCVs), PCV10 and PCV13, are currently used in different countries. We have previously reported the effectiveness of PCV7, following its introduction in Israel and before PCVs were introduced in Palestine. Here, we extended the study and compared the initial impact of PCV10 to that of PCV7/13.

methodsFour cross-sectional surveys of S. pneumoniae carriage among children <5y through 2009-2014 were preformed among two proximate populations, living under two distinct health authorities, with different vaccination policies. In East-Jerusalem (EJ), PCV7 was implemented in 2009 and replaced by PCV13 in late 2010, while in Palestine (PA), PCV10 was implemented in 2011.

resultsA total of 1267 and 2414 children from EJ and PA were screened. In 2014, S. pneumoniae was detected in 30.7% and 28.6% of the children in EJ and PA respectively Implementation of both PCV7 (in EJ) and PCV10 (in PA) did not affect overall S. pneumoniae carriage, but resulted in a significant decrease in the prevalence of vaccine-type strains. In the pre-vaccine era, VT7/VT13 strains consisted 47.0%/62.0% and 41.2%/54.8% of pneumococci in EJ and PA, respectively. A 48.6% and 53.9% decrease in VT7 strains was observed within 3 years of PCV7 implementation in EJ (p = 0.001) and PCV10 in PA (p<0.0001), respectively. These vaccination policies also resulted in ~50% reduction in VT13-added serotypes especially 6A (from 11.0% to 0.0% (EJ) and 9.5% to 4.9% (PA)). Three years after PCV13 implementation in EJ, an additional 67% decrease in VT13 strains was observed, yet an increase in serotype 3 was observed (0.0% to 3.4%, p = 0.056). While the prevalence of VT13 strains decreased significantly during the study period, the overall carriage rate didn't change significantly due to replacement with non-VT13 strains which comprised 89.8% and 70.7% of all pneumococci, in EJ and in PA respectively in the last study year.

conclusionsWithin the first three years following PCV implementation, we observed similar reductions in carriage of VT10 and VT13 strains with either vaccination policies, with no effect on overall carriage. Further follow-up is needed to compare the long-term effects.

Indexed as

Carrier StateChild, PreschoolCross-Sectional StudiesFemaleHumansInfantInternational CooperationIsraelMaleNasopharynxPneumococcal InfectionsPneumococcal VaccinesPrevalenceStreptococcus pneumoniaeVaccinationVaccines, ConjugatePneumococcal VaccinesVaccines, Conjugate

Identifiers

PMID30418989
PMCPMC6231627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.